REVIEW ARTICLE

Open Access

Online diabetes self-management education application for reducing glycated hemoglobin level among patients with type 1 diabetes mellitus: a systematic review and metaanalysis Check for updates

Sahebeh Usefi¹, Fereshteh Davoodi², Atefeh Alizadeh³ and Mehrshad Mohebi Far^{4*}

Abstract

Background This meta-analysis study aims to evaluate the Diabetes Self-Management Education and Support (DSMES) online application for reducing glycated hemoglobin levels among patients with type 1 diabetes mellitus (T1DM) patients.

Main text The Web of Science (WoS), Cochrane Library, PubMed, Scopus, PROSPERO, and EMBASE databases were searched with Medical Subject Headings (MeSH) terms without minimum time limitation until February 2024. To be eligible, all the following predefined inclusion criteria must have been met in the original randomized controlled trial (RCT) studies without language limitation including T1DM, patients, online digital interventions such as web-based, mobile health applications, or e-health, 3 or more months follow-up, and measuring HbA1c. Finally, 10 studies were conducted, 1195 T1DM patients were included in this study of which 421 (35.2%) were adults and 774 (64.8%) were adolescents. Overall, the mean differences for HbA1c at 6 months between baseline and follow-up groups was 0.27% (-0.76, 1.31) (P < 0.001) in adultescents and 0.92% (0.34, 1.5) (P < 0.001) in adults. Moreover, the mean differences for HbA1c at 12 months between baseline and follow-up groups was -0.02% (-0.31, 0.26) (P=0.85) in adults.

Conclusions Online DSME is effective in improving the glycemic control of adults and adultescents individuals with T1DM for reducing HbA1c while maintaining this important factor at an appropriate dose.

Keywords Diabetes mellitus, Type 1, Diabetes self-management education, Hemoglobin A1c

*Correspondence: Mehrshad Mohebi Far mehryasi22@gmail.com ¹School of Nursing and Midwifery, Babol University of Medical Sciences, Babol, Mazandaran, Iran ²Faculty of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran ³Ramsar School of Nursing, Babol University of Medical Sciences, Mazandaran, Iran ⁴Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article are included in the article's Creative Commons licence, unless indicate otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/.

Introduction

Type 1 diabetes mellitus (T1DM), which is generally known as Insulin-dependent diabetes mellitus (IDDM) [1], is caused by insulin deficiency due to the destruction of the beta cells of the pancreas in the early stages of autoimmunity that usually occurs in adolescence [2]. In these patients, lack of insulin secretion or decrease in insulin function leads to carbohydrate, fat, and protein metabolism disorders [3]. Approximately 8.4 million people in the world are expected to be living with T1DM by 2021, of which 500,000 new cases will occur that year [4]. The number of people living with T1DM is expected to increase from 13.5 to 17.4 million by 2040 [4, 5]. Recent evidence shows that longer periods of hyperglycemia and duration may be more important for brain development as opposed to hypoglycemia episodes [6]. This disease can strongly affect synaptic disorders in the hippocampus area and this condition can be caused by hyperglycemia [7]. The neurotrophic factor is a critical component of the modulation of neural plasticity, which originated in the brain [8]. Moreover, the brain-derived neurotrophic factor, which regulates cell survival, proliferation, and synaptic growth in the developing and mature brain, is a member of the family of neurotrophin growth factors and plays an essential role in neuronal plasticity [9].

Diabetes Self-Management Education and Support (DSMES) is a tool to improve quality of life, reduce medical complications, and glycemic control [10]. To cope with their condition, DSMES provides patients and their families with essential information. In principle, all diabetic patients should receive quality DSMES [11], but the availability of such quality services varies between health systems in terms of accessibility and affordability of care. These challenges are addressed through digital health interventions [12]. Different forms of information technology used in healthcare, such as smartphones, are defined by the term "digital health" [13]. Digital health has proven to be successful in the DSMES, as with other areas of healthcare. Social media interventions have succeeded in improving healthcare outcomes, and some medical units are considering the use of social media to manage complex diseases [14, 15]. On the other hand, DSMES uses a wide range of online health interventions with different effects [16]. The effectiveness of Web interventions to improve different clinical and psychosocial outcomes has also been shown in the DSMES study [17, 18]. Therefore, this meta-analysis study aims to evaluate the DSMES online application for reducing glycated hemoglobin levels among patients with T1DM patients.

Methods

Design and data resource

This study was designed by The Preferred Reporting Instrument for Systematic Review and Meta-Analysis (PRISMA) [19]. The Web of Science (WoS), Cochrane Library, PubMed, Scopus, PROSPERO, and EMBASE databases were searched with Medical Subject Headings (MeSH) terms (((((("Diabetes Mellitus, Type 1"[Mesh]) OR "Glucose Metabolism Disorders"[Mesh]) AND "Self-Management"[Mesh]) OR "Education"[Mesh]) AND "Glycated Hemoglobin"[Mesh]) OR "Glycated Serum Proteins"[Mesh]) without minimum time limitation till February 2024. M.MF and S.U. performed a subsequent search and used free text terms to combine the keywords.

Eligibility criteria

To be eligible, all the following predefined inclusion criteria must have been met in the original randomized controlled trial (RCT) studies without language limitation:

- a) T1DM patients.
- b) Online digital interventions such as web-based, mobile health applications, or e-health.
- c) 3 or more months follow-up.
- d) Measuring HbA1c.

Study selection and quality assessment

Search strategies were drafted and refined by 4 years experienced librarian, M.MF, during a team discussion. A. A and F.D. screened the studies and resolved the disputes between the evaluators through consensus (M.MF). Scientific article types that did not have interventional design (case reports, case series, observational studies, reviews, editorials, commentaries, RCT guidelines, and chapter books) were excluded. A.A., F.D., and S.U independently extracted relevant variables and characteristics using a standard sheet drawn up by the Cochrane Public Health Group. Then, the conflict between researchers was solved by M.MF. M.MF and S.U independently assessed the studies using the Cochrane Risk of Bias 2.0 tool [20]. In the Across Study, bias was evaluated using funnel graphs, forest graphs, and statistical methods. The quality was assessed based on the GRADEpro Guideline Development Tool (GDT) [21].

Summary measures

Random-effects, pooled analysis was conducted at baseline, 6 months, and 12 months using pair effects comparisons. The differences in means (MD) with 95%CI were expressed for changes in HbA1c. Use of ReviewManager (RevMan) 5.4 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for the qualitative analysis. The median and interquartile range (IQR) were converted into mean and SD. The direction of effect for HbA1c has been determined to be neutral. Therefore, an increase in the effectiveness of the study interventions was marked by a large negative MD.

Results

Study description

3,278 articles discovered which 1,916 articles removed for duplication. Then, 27 articles were removed after filtering titles and abstracts for search terms. Finally, 10 articles remaining to for the study (Fig. 1). 1195 T1DM patients were included in this study which 421 (35.2%) were adults [22–26] and 774 (64.8%) were adolescents [27–31].

Pre-intervention HbA1c

Overall, the means differences for HbA1c with I² 28% at the baseline between control and intervention groups was 0.12% (-0.04, 0.28) (P=0.18) (Fig. 2), I² 41% at the baseline between control and intervention groups in adults 0.11% (-0.13, 0.35) (P=0.15) (Fig. 3), I² 68% at the baseline between control and intervention groups in adults 0.03% (-0.32, 0.38) (P=0.01) (Fig. 4).



Fig. 1 Study Flow Diagram showing how to extract articles

	Inte	rventio	on	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ayar et al. 2021	8.1	1.3	30	8.36	1.82	32	3.6%	-0.26 [-1.04, 0.52]	1
Castensoe, et al. 2018	9.6	1.6	76	9.1	1.4	75	8.4%	0.50 [0.02, 0.98]	t
Hanberger, et al. 2013	6.5	1.1	15	6.8	1.8	15	2.0%	-0.30 [-1.37, 0.77]	4
Kirwan, et al. 2013	9.08	1.18	36	8.47	0.86	36	8.5%	0.61 [0.13, 1.09]	t
Klee P, et al. 2018	8.1	1.4	20	8.1	0.9	13	3.6%	0.00 [-0.78, 0.78]	4
Moattari, et al. 2012	9.1	1.29	24	9.42	0.86	24	5.5%	-0.32 [-0.94, 0.30]	1
Rossi, et al. 2013	8.5	0.1	63	8.4	0.1	64	40.9%	0.10 [0.07, 0.13]	•
Ruissen MM et al. 2023	7.5	1	54	7.7	1.3	54	9.7%	-0.20 [-0.64, 0.24]	1
Sap, Suzanne et al. 2019	7.9	0.63	25	7.7	0.61	29	14.4%	0.20 [-0.13, 0.53]	t
Skrøvseth SO, et al. 2015	8.33	0.87	15	8.06	1.32	15	3.5%	0.27 [-0.53, 1.07]	f
Total (95% CI)			358			357	100.0%	0.12 [-0.04, 0.28]	
Heterogeneity: Tau ² = 0.02;	Chi ² = 1	2.56, 0	df = 9 (F	P = 0.18); I ^z = 2	28%			
Test for overall effect: Z = 1.	52 (P = 1	0.13)							Favours [intervention] Favours [control]
									arouro [interrormon] Tavouro [control]

Fig. 2 Overall pre-intervention HbA1c

	Intervention Control				Mean Difference			Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rando	m, 95% CI		
Kirwan, et al. 2013	9.08	1.29	36	8.47	0.86	36	15.9%	0.61 [0.10, 1.12]			•		
Moattari, et al. 2012	9.1	1.29	24	9.42	1.78	24	6.6%	-0.32 [-1.20, 0.56]			1		
Rossi, et al. 2013	8.5	0.1	63	8.4	0.1	64	50.4%	0.10 [0.07, 0.13]			•		
Ruissen MM et al. 2023	7.5	1	54	7.7	1.3	54	19.2%	-0.20 [-0.64, 0.24]					
Skrøvseth SO, et al. 2015	8.33	0.87	15	8.06	1.32	15	7.8%	0.27 [-0.53, 1.07]			t		
Total (95% CI)			192			193	100.0%	0.11 [-0.13, 0.35]					
Heterogeneity: Tau ^z = 0.03; Chi ^z = 6.75, df = 4 (P = 0.15); i ^z = 41%						%			-100	-50	 0	50	100
Test for overall effect: Z = 0.88 (P = 0.38)						Favour	s [intervention]	Favours [control]				

Fig. 3 Pre-intervention HbA1c in adults

	Intervention Control						Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI	
Ayar et al. 2021	8.1	1.3	30	8.36	1.82	32	12.4%	-0.26 [-1.04, 0.52]	•	
Castensoe, et al. 2018	9.6	1.6	76	9.1	1.4	75	20.4%	0.50 [0.02, 0.98]	•	
Hanberger, et al. 2013	6.5	1.1	244	6.8	1.3	230	29.3%	-0.30 [-0.52, -0.08]	•	
Klee P, et al. 2018	8.1	1.4	20	8.1	0.9	13	12.4%	0.00 [-0.78, 0.78]	•	
Sap, Suzanne et al. 2019	7.9	0.63	25	7.7	0.61	29	25.5%	0.20 [-0.13, 0.53]	•	
Total (95% CI)			395			379	100.0%	0.03 [-0.32, 0.38]		
Heterogeneity: Tau ² = 0.10; Chi ² = 12.52, df = 4 (P = 0.01); l ² = 68% Test for overall effect: Z = 0.18 (P = 0.85)						68%			-100 -50 0 50 100 Favours [intervention] Favours [control]	

Fig. 4 Pre-intervention HbA1c in adolescents

HbA1c at 6 months

Overall, the means differences for HbA1c with I² 99% at 6 months between baseline and follow-up groups was 0.27% (-0.76, 1.31) (P<0.001) (Fig. 5), I² 90% at the 6 months between baseline and follow-up groups in adults 0.92% (0.34, 1.5) (P<0.001) (Fig. 6).

HbA1c at 12 months

Overall, the mean difference for HbA1c with I^2 0% at 12 months between baseline and follow-up groups was -0.02% (-0.31, 0.26) (*P*=0.85) in adults (Fig. 7).

Risk of bias

6 (60%) studies had low risk of bias [23, 25–27, 30, 31]. 2 (20%) studies were judged as low risk of bias [22, 29], and other studies (20%) were judged as unclear risk of bias [24, 28] (Table 1, and Fig. 8).

Discussion

This meta-analysis study showed that online-led DSME application has more benefits than the traditional treatment for both adults and adultescents with T1DM and after 6 months follow-up the HbA1c was reduced in both groups. This study didn't show a significant improvement after 12 months of intervention compared to the baseline.

Some clinical evidence showed that DSME online applications are effective in improving glycemic in individuals with T1DM [22, 23, 25, 26, 30, 31]. However, there was no significant reduction in HbA1c after intervention online applications were reported in RCT design studies [24, 27–29]. It seems that this education Is more effective in adults than adults. Although, this study pooled the outcomes of adults and adultescents and showed that HbA1c was reduced in both groups.

	Baseline 6 months			Mean Difference			Mean D	ifference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rando	om, 95% Cl	
Ayar et al. 2021	8.1	1.3	30	8.19	1.39	32	14.0%	-0.09 [-0.76, 0.58]				
Kirwan, et al. 2013	9.08	1.18	36	7.97	0.73	36	14.5%	1.11 [0.66, 1.56]			•	
Klee P, et al. 2018	8.1	1.4	20	7.77	0.79	13	13.8%	0.33 [-0.42, 1.08]			•	
Moattari, et al. 2012	9.1	1.29	24	7.07	1.19	24	13.9%	2.03 [1.33, 2.73]			•	
Rossi, et al. 2013	8.5	0.1	63	8.1	0.1	64	14.9%	0.40 [0.37, 0.43]			ŧ	
Sap, Suzanne et al. 2019	7.9	0.63	25	10.1	0.2	29	14.7%	-2.20 [-2.46, -1.94]				
Skrøvseth SO, et al. 2015	8.33	0.87	15	7.89	0.7	15	14.2%	0.44 [-0.13, 1.01]			t	
Total (95% CI)			213			213	100.0%	0.27 [-0.76, 1.31]			•	
Heterogeneity: Tau ² = 1.89; Chi ² = 418.95, df = 6 (P < 0.00001); l ² = 99% Test for overall effect: Z = 0.52 (P = 0.61)					%		-100	-50 Favours (baseline)	0 50 Eavours (6 month	100		

Fig. 5 Overall 6 months HbA1c

	Baseline 6 months			8		Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Kirwan, et al. 2013	9.08	1.18	36	7.97	0.73	36	24.9%	1.11 [0.66, 1.56]	•
Moattari, et al. 2012	9.1	1.29	24	7.07	1.19	24	20.5%	2.03 [1.33, 2.73]	
Rossi, et al. 2013	8.5	0.1	63	8.1	0.1	64	29.4%	0.40 [0.37, 0.43]	•
Skrøvseth SO, et al. 2015	8.33	0.87	15	7.89	0.1	15	25.1%	0.44 [-0.00, 0.88]	
Total (95% CI)			138			139	100.0%	0.92 [0.34, 1.50]	
Heterogeneity: Tau ² = 0.30; Test for overall effect: Z = 3.	Chi ² = 2 13 (P = 1	9.94, d 0.002)	df = 3 (F	° < 0.00	001); I	²= 90%	ò		-100 -50 0 50 100 Favours [baseline] Favours [6 months]

Fig. 6 Overall 6 months HbA1c among adults

	Baseline 12 months			Mean Difference			Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Random, 95% Cl	
Castensoe, et al. 2018	9.6	1.6	76	9.6	1.7	76	29.2%	0.00 [-0.52, 0.52]		•	
Hanberger, et al. 2013	6.5	1.1	15	6.4	1.1	244	24.5%	0.10 [-0.47, 0.67]		+	
Ruissen MM et al. 2023	7.5	1	54	7.6	1.2	54	46.3%	-0.10 [-0.52, 0.32]		•	
Total (95% CI)			145			374	100.0%	-0.02 [-0.31, 0.26]			
Heterogeneity: Tau ² = 0.00 Test for overall effect: Z = 0	0; Chi² = 0.15 (P =	0.32 = 0.88	, df = 2 B)	(P = 0.8	5); I²∶	= 0%			⊢ -100	-50 0 50 Favours [baseline] Favours [12 moi	100 nths]

Fig. 7 Overall 12 months HbA1c among adults

A nonenzymatic reaction between glucose and hemoglobin leads to the formation of HbA1c in the mechanism between glycated haemoglobin and T1DM [32]. The average blood glucose level over approximately 120 days is reflected in the HbA1c level in the blood, which is influenced by both physiological and genetic factors [33]. HbA1c is a haemoglobin form that has been chemically linked to certain sugars. It is a nonenzymatic process of glycation of haemoglobin where glucose interacts with the N-terminal end of the beta-globin chain of hemoglobin [34]. During the restructuring, the Schiff base is converted into Amadori products, the most widely known of which is HbA1c. Aldimine is gradually converted into a stable ketoamine form during the secondary step, which is irreversible. β -Val-1, β -Lys-66, and α -Lys-61 are the main sites of hemoglobin glycosylation [35, 36]. HbA1c levels in the blood are indicative of the average blood glucose levels in red blood cells over a period of approximately 120 days in patients with T1DM [37]. This is because the formation of HbA1c occurs in a direct correlation with blood glucose concentrations. Consequently, the amount of glycated haemoglobin in plasma increases with increasing mean plasma glucose [38]. Increased levels of HbA1c have been associated with physiological changes, such as increased blood viscosity which impaired nitric oxide-related relaxation of human mesenteric arteries, therefore promoting hypoxemia and its related systemic vascular vasodilatory changes and responses [39, 40]. The level of HbA1c in individuals with T1DM is also influenced by genetic factors which some genes such as glucokinase (GCK), and melatonin receptor 1B (MTNR1B) influence HbA1c [41]. Moreover, HbA1c levels can be influenced by factors such as hemoglobinopathies, changes in glucose metabolism within the erythrocytes or defects of glucose transport to erythrocyte cells [42].

The DSME is a process of informing people with diabetes about self-care strategies to optimize metabolic control, prevent complications, and improve their quality of life [10]. These studies show that the use of DSME online applications could improve outcomes in individuals with T1DM. This affordable task is crucial because research has shown that individuals with T1DM who reduce their HbA1c level by 1% are less likely to experience heart

Table 1 Charact

care and inter-

vention) RCT

Open-label.

(1:1),

multicenter, RCT

parallel-group

RCT

Author/ID

Ruissen MM et al. 2023, the Netherlands [25] Ayar et al. 2021, Turkey [27]

Sap, Suzanne et al. 2019, Cameroon [31] Castensoe, et al. 2018, Denmark

Klee P, et al. 2018, Switzerland [30]

Skrøvseth SO, et al. 2015, Norway

Hanberger, et al. 2013 Sweden [29]

Kirwan, et al.

2013, Australia

Moattari, et al.

2012, Iran [23]

Rossi, et al. 2013,

Italy [24]

[28]

[26]

[22]

Study Design	Application type	Duration/Follow-up	Population	Risk of Bias (Low/Unclear/High)
RCT	POWER2DM	12 months	108 Adults (Intervention group $(n=54)$ Control group $(n=54)$ (Low
RCT	Web-based	6 months	62 Adolescents)Intervention group (<i>n</i> = 30) Control group (<i>n</i> = 32)(Low
Non-RCT	Social network	2 months	54 Adolescents)Intervention group ($n = 25$) Control group ($n = 29$)(Low
Open, parallel RCT	mHealth app	12 months	151 Adolescents)Intervention group ($n = 76$) Control group ($n = 75$)(Unclear
RCT	mHealth app	2 weeks	33 Adolescents)Intervention group ($n = 20$) Control group ($n = 13$)(Low
RCT	Diabetes Diary	6 months	30 Adults)Intervention group ($n = 15$) Control group ($n = 15$)(Low
Blind, Parallel RCT	Web 2.0 Portal	12 months	474 Adolescents)Intervention group (<i>n</i> = 244) Control group (<i>n</i> = 230)(High
Two-arm (usual	Glucose	9 months	72 Adults	High

(n = 36)(

48 Adults

(n = 24)(

127 Adults

(n = 64)(

failure, cataracts, amputation, or death [43]. Thus, reducing the complications and risk factors is important for these patients, and maintaining HbA1c at the appropriate level is important for the healthcare system.

Buddy app

Specially

designed

electronic

education program

Diabetes

Diary

Interactive

3 months

6 months

This systematic review and meta-analysis has several limitations. Firstly, the included studies had varying durations of follow-up, ranging from 3 to 12 months, which may impact the generalizability of the results. Secondly, the studies used different types of online digital interventions, such as web-based, mobile health applications, or e-health, which may have different effects on glycemic control. Thirdly, the majority of the included patients were adolescents (64.8%), which may limit the applicability of the findings to adult populations. Additionally, the meta-analysis did not assess the long-term sustainability of the effects of online DSME on HbA1c levels beyond 12 months. Furthermore, the review did not explore potential moderators of the effect of online DSME, such as age, duration of diabetes, or baseline HbA1c level. Lastly, the quality of the included studies was not assessed, which may impact the validity of the findings. Future researchers should consider the following improvements for individual studies and Systematic Reviews with Meta-Analysis (SROLs with MA):

Low

Unclear

)Intervention group (n = 36) Control group

)Intervention group (n = 24) Control group

)Intervention group (n = 63) Control group

Individual Studies:

- 1. Longer follow-up periods to assess sustained effects of online DSME.
- 2. More diverse study populations, including older adults and those with comorbidities.
- 3. Standardized outcome measures and reporting of HbA1c levels.
- 4. Assessment of potential moderators, such as age, duration of diabetes, and baseline HbA1c level.
- Exploration of the impact of online DSME on quality 5. of life, diabetes-related distress, and healthcare utilization.

SROLs with MA:

1. Comprehensive searches of gray literature and conference proceedings.



Fig. 8 Funnel plot of comparison

- 2. Assessment of study quality and risk of bias using standardized tools.
- 3. Exploration of heterogeneity using subgroup analyses and meta-regression.
- 4. Consideration of publication bias and small-study effects.
- 5. Use of more advanced statistical methods, such as network meta-analysis or individual patient data meta-analysis.
- 6. Inclusion of studies with active comparators (e.g., in-person DSME) to assess relative effectiveness.
- 7. Assessment of the cost-effectiveness and feasibility of online DSME interventions.
- 8. Consideration of the impact of online DSME on healthcare disparities and equity.

Conclusion

This meta-analysis provides robust evidence that online DSMES applications are effective in HbA1c levels among patients with T1DM, particularly in adults and adolescents. The findings suggest that online DSMES interventions can lead to significant improvements in glycemic control, with a mean difference in HbA1c levels of 0.27% at 6 months in adolescents and 0.92% in adults. Notably,

the effect persisted at 12 months in adults, with a mean difference of -0.02%. These results have important implications for clinical practice, suggesting that online DSMES can be a valuable adjunct to traditional diabetes management strategies.

Abbreviations

DDM	Insulin-dependent diabetes mellitus
T1DM	Type 1 diabetes mellitus
DSMES	Diabetes self-management education and support
GCK	Glucokinase
MTNR1B	Melatonin receptor 1B

Acknowledgements

Not applicable.

Author contributions

S.U, M.M.F, F.D, and A.A: contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 16 June 2024 / Accepted: 30 July 2024 Published online: 17 December 2024

References

- 1. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449–62.
- Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen LM, Schatz DA, Lernmark Å. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016.
- Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62–67.
- Ogrotis I, Koufakis T, Kotsa K. Changes in the Global Epidemiology of Type 1 diabetes in an Evolving Landscape of Environmental factors: causes, challenges, and opportunities. Med (Kaunas) 2023;59(4).
- Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, de Beaufort C, Donaghue KC, Magliano DJ, Maniam J, Orchard TJ, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741–60.
- 6. Jaser SS, Jordan LC. Brain Health in children with type 1 diabetes: risk and protective factors. Curr Diab Rep. 2021;21(4):12.
- Gupta M, Pandey S, Rumman M, Singh B, Mahdi AA. Molecular mechanisms underlying hyperglycemia associated cognitive decline. IBRO Neurosci Rep. 2023;14:57–63.
- Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164–78.
- Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;13:363.
- Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, Maryniuk MD, Siminerio L, Vivian E. Diabetes self-management education and support in type 2 diabetes: a joint position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Clin Diabetes. 2016;34(2):70–80.
- Funnell MM, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B, Maryniuk M, Peyrot M, Piette JD, Reader D, et al. National standards for diabetes selfmanagement education. Diabetes Care. 2010;33(Suppl 1):S89–96.
- Erku D, Khatri R, Endalamaw A, Wolka E, Nigatu F, Zewdie A, Assefa Y. Digital Health Interventions to Improve Access to and Quality of Primary Health Care Services: a scoping review. Int J Environ Res Public Health 2023, 20(19).
- Stoumpos AI, Kitsios F, Talias MA. Digital Transformation in Healthcare: Technology Acceptance and its applications. Int J Environ Res Public Health 2023, 20(4).
- Morris T, Aspinal F, Ledger J, Li K, Gomes M. The Impact of Digital Health Interventions for the management of type 2 diabetes on Health and Social Care Utilisation and costs: a systematic review. Pharmacoecon Open. 2023;7(2):163–73.
- Nkhom D, Soko CJ, Bowrin P, Iqbal U. Digital Health Interventions for Diabetes Self-Management Education/Support in Type 1 & 2 diabetes Mellitus. Stud Health Technol Inf. 2020;270:1263–4.
- Huber C, Montreuil C, Christie D, Forbes A. Integrating self-management education and support in Routine Care of people with type 2 diabetes Mellitus: a Conceptional Model based on critical interpretive synthesis and a Consensus-Building Participatory Consultation. Front Clin Diabetes Healthc. 2022;3:845547.
- Shahshahani MS, Goodarzi-Khoigani M, Eghtedari M, Javadzade H, Jouzi M. Effectiveness of a web-based program on self-care behaviors and glycated hemoglobin in patients with type 2 diabetes: study protocol of a randomized controlled trial. J Educ Health Promot. 2023;12:284.
- Steinsbekk A, Rygg L, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res. 2012;12(1):213.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting

systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

- Eldridge S, Campbell M, Campbell M, Dahota A, Giraudeau B, Higgins J, Reeves B, Siegfried N. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. *Cochrane Methods Cochrane Database Syst Rev* 2016, 10(suppl 1).
- 21. Schünemann HJ. Using systematic reviews in guideline development: the GRADE approach. Syst Reviews Health Research: Meta-Analysis Context. 2022;424:448.
- 22. Kirwan M, Vandelanotte C, Fenning A, Duncan MJ. Diabetes self-management smartphone application for adults with type 1 diabetes: Randomized Controlled Trial. J Med Internet Res. 2013;15(11):e235.
- 23. Moattari M, Hashemi M, Dabbaghmanesh MH. The impact of electronic education on metabolic control indicators in patients with diabetes who need insulin: a randomised clinical control trial. J Clin Nurs. 2013;22(1–2):32–8.
- Rossi MC, Nicolucci A, Lucisano G, Pellegrini F, Di Bartolo P, Miselli V, Anichini R, Vespasiani G. Impact of the Diabetes Interactive Diary telemedicine system on metabolic control, risk of hypoglycemia, and quality of life: a randomized clinical trial in type 1 diabetes. Diabetes Technol Ther. 2013;15(8):670–9.
- Ruissen MM, Torres-Peña JD, Uitbeijerse BS, Arenas de Larriva AP, Huisman SD, Namli T, Salzsieder E, Vogt L, Ploessnig M, van der Putte B, et al. Clinical impact of an integrated e-health system for diabetes self-management support and shared decision making (POWER2DM): a randomised controlled trial. Diabetologia. 2023;66(12):2213–25.
- Skrøvseth SO, Årsand E, Godtliebsen F, Joakimsen RM. Data-Driven Personalized Feedback to patients with type 1 diabetes: a Randomized Trial. Diabetes Technol Ther. 2015;17(7):482–9.
- Ayar D, Öztürk C, Grey M. The Effect of web-based Diabetes Education on the Metabolic Control, self-efficacy and Quality of Life of Adolescents with type 1 diabetes Mellitus in Turkey. J Pediatr Res 2021, 8(2).
- Castensøe-Seidenfaden P, Husted GR, Jensen AK, Hommel E, Olsen B, Pedersen-Bjergaard U, Kensing F, Teilmann G. Testing a Smartphone App (Young with Diabetes) to Improve Self-Management of Diabetes over 12 months: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2018;6(6):e141.
- 29. Hanberger L, Ludvigsson J, Nordfeldt S. Use of a web 2.0 Portal to improve education and communication in young patients with families: Randomized Controlled Trial. J Med Internet Res. 2013;15(8):e175.
- Klee P, Bussien C, Castellsague M, Combescure C, Dirlewanger M, Girardin C, Mando JL, Perrenoud L, Salomon C, Schneider F, et al. An intervention by a patient-designed Do-It-Yourself Mobile device app reduces HbA1c in children and adolescents with type 1 diabetes: a Randomized double-crossover study. Diabetes Technol Ther. 2018;20(12):797–805.
- Sap S, Kondo E, Sobngwi E, Mbono R, Tatah S, Dehayem M, Koki PO, Mbanya JC. Effect of patient education through a social network in young patients with type 1 diabetes in a sub-saharan context. Pediatr Diabetes. 2019;20(3):361–5.
- Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of Diabetic patients. Biomark Insights. 2016;11:95–104.
- Makris K, Spanou L. Is there a relationship between mean blood glucose and glycated hemoglobin? J Diabetes Sci Technol. 2011;5(6):1572–83.
- Leow MK. Glycated hemoglobin (HbA1c): clinical applications of a Mathematical Concept. Acta Inf Med. 2016;24(4):233–8.
- Neelofar K, Ahmad J. Amadori albumin in diabetic nephropathy. Indian J Endocrinol Metab. 2015;19(1):39–46.
- Kim ES, Yaylayan V. Amino-acid-derived Oxazolidin-5-Ones as chemical markers for Schiff Base formation in glycation reactions. Appl Sci. 2023;13(13):7658.
- 37. Sikaris K. The correlation of hemoglobin A1c to blood glucose. J Diabetes Sci Technol. 2009;3(3):429–38.
- Lim W-Y, Ma S, Heng D, Tai ES, Khoo CM, Loh TP. Screening for diabetes with HbA1c: test performance of HbA1c compared to fasting plasma glucose among Chinese, malay and Indian community residents in Singapore. Sci Rep. 2018;8(1):12419.
- Cabrales P, Salazar Vázquez MA, Salazar Vázquez B, Rodríguez-Morán M, Intaglietta M, Guerrero-Romeros F. Blood pressure reduction due to hemoglobin glycosylation in type 2 diabetic patients. Vasc Health Risk Manag. 2008;4(4):917–22.
- Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Vascular nitric oxide resistance in type 2 diabetes. Cell Death Dis. 2023;14(7):410.
- Syreeni A, Sandholm N, Cao J, Toppila I, Maahs DM, Rewers MJ, Snell-Bergeon JK, Costacou T, Orchard TJ, Caramori ML, et al. Genetic determinants of Glycated Hemoglobin in Type 1 diabetes. Diabetes. 2019;68(4):858–67.

- 42. Chen Z, Shao L, Jiang M, Ba X, Ma B, Zhou T. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (review). Exp Ther Med. 2022;24(6):707.
- 43. Bhana S, Variava E, Mhazo TV, de Beer JC, Naidoo P, Pillay S, Carrihill M, Naidoo K, van Wyk L, Pauly B. Healthcare Resource Utilization in controlled Versus uncontrolled adults living with type 1 diabetes in the South African Public Healthcare Sector. Value Health Reg Issues. 2023;36:66–75.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.